Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Preferentially expressed antigen in melanoma (PRAME)-derived peptide-human leukocyte antigen (HLA) complexes represent a class of tumor-associated antigens presented on the cell surface of various malignancies. PRAME is a cancer-testis antigen that is highly expressed in a wide range of solid tumors (such as melanoma, non-small cell lung cancer, ovarian cancer, and synovial sarcoma) and hematological malignancies (such as acute myeloid leukemia), while its expression in healthy tissues is restricted to immune-privileged sites like the testes and endometrium. Intracellular PRAME proteins are degraded by the immunoproteasome into peptide fragments, such as the ALYVDSLFFL (ALY) or SLLQHLIGL peptides, which are then loaded onto HLA class I molecules (most commonly HLA-A*02:01 or HLA-A*24:02) and transported to the cell surface. These peptide-HLA complexes serve as highly specific targets for the immune system, allowing T-cell receptors (TCRs) to recognize and eliminate cancer cells. Therapeutic strategies targeting these complexes include adoptive T-cell therapies, TCR-mimic chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engagers. These agents bind specifically to the PRAME-pHLA complex, redirecting and activating T-cells to induce tumor cell cytolysis. Clinical development of these therapies requires patient selection based on both PRAME expression and specific HLA haplotype matching (e.g., HLA-A*02:01). Notable safety concerns associated with these therapies include cytokine release syndrome (CRS), cytopenias from pre-conditioning lymphodepletion, and potential on-target off-tumor toxicities, although the restricted expression of PRAME in normal tissues generally provides a favorable therapeutic window.
Drugs targeting PRAME-derived peptide-HLA complexes work by redirecting the host immune system to recognize and destroy cancer cells. This is achieved through several modalities: adoptive T-cell receptor (TCR) T-cell therapies (which use patient-derived T-cells engineered with high-affinity TCRs), TCR-mimic chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engagers (which bridge the tumor's peptide-HLA complex with CD3 on T-cells to trigger direct cytolysis).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Preferentially expressed antigen in melanoma-derived peptide-human leukocyte antigen complexes (PRAME-pHLA complexes).